Vitavirin powder for solution for oral administration 90mg in bags No. 7

Name:
Vitavirin. Release formPowder. MNNIMidazolylethanamide pentanedioic acid. FTHAn antiviral agent.
Description:
Powder from white to white with a yellowish tint, with a lemon smell, soft lumps are allowed. Composition Active substance: pentanedioic acid imidazolylethanamide – 90 mg; excipients: sucralose, lemon lime flavor, mannitol (E421). Pharmacotherapeutic group Antiviral agents for systemic use. Antivirals of direct action. ATC code: J05AX21 Pharmacological action Pharmacodynamics Antiviral drug. In preclinical and clinical studies, imidazolylethanamide pentanedioic acid has shown efficacy against influenza A (A(H1N1), including swine A(H1N1)pdmO9, A(H3N2), A(H5N1) and type B viruses, adenovirus, parainfluenza, respiratory syncytial virus; in preclinical studies: coronavirus, metapneumovirus, enteroviruses, including Coxsackie virus and rhinovirus. Vitavirin promotes accelerated elimination of viruses, shortening the duration of the disease, reducing the risk of complications. The mechanism of action is implemented at the level of infected cells due to stimulation factors of innate immunity suppressed by viral proteins.In experimental studies, in particular, it has been shown that imidazolylethanamide of pentanedioic acid increases the expression of the type 1 interferon receptor IFNAR on the surface of epithelial and immunocompetent cells.An increase in the density of interferon receptors leads to an increase in cell sensitivity to en pregenic interferon. The process is accompanied by activation (phosphorylation) of the STAT1 transmitter protein, which transmits a signal to the cell nucleus for the induction of antiviral genes. It has been shown that under conditions of infection, the drug stimulates the production of the antiviral effector protein MxA, which inhibits the intracellular transport of ribonucleoproteins of various viruses, slowing down the process of viral replication. The drug Vitavirin causes an increase in the interferon content in the blood to the physiological norm, stimulates and normalizes the reduced α-interferon producing ability of blood leukocytes, stimulates the γ-interferon producing ability of leukocytes. Causes the generation of cytotoxic lymphocytes and increases the content of NK-T cells with high killer activity against virus-infected cells. The anti-inflammatory effect is due to the suppression of the production of key pro-inflammatory cytokines (tumor necrosis factor (TNF-α), interleukins (1L-1β and IL-6)), a decrease in the activity of myeloperoxidase. Experimental studies have shown that the combined use of pentanedioic acid imidazolylethanamide with antibiotics increases the effectiveness of therapy in a model of bacterial sepsis, including that caused by penicillin-resistant strains of staphylococcus aureus. Conducted experimental toxicological studies indicate a low level of toxicity and a high safety profile of the drug. In terms of acute toxicity, imidazolylethanamide pentanedioic acid belongs to the 4th toxicity class – “Low-toxic substances” (during the determination of LD50 in experiments on acute toxicity, lethal doses of the drug could not be determined). The drug does not have mutagenic, immunotoxic, allergenic and carcinogenic properties, does not have a local irritating effect. Vitavirin does not affect reproductive function, does not have embryotoxic and teratogenic effects. With a course of taking the drug once a day, it accumulates in the internal organs and tissues. At the same time, the qualitative characteristics of the pharmacokinetic curves after each injection of the drug were identical: a rapid increase in the concentration of the drug after each injection 0.5-1 hour after administration and then a slow decrease by 24 hours. Metabolism The drug is not metabolized in the body and is excreted unchanged. Elimination The main elimination process occurs within 24 hours. During this period, 80% of the dose taken is excreted: 34.8% is excreted in the time interval from 0 to 5 hours and 42.5% in the time interval from 5 to 24 hours. Of these, 77% is excreted through the intestines and 23% through the kidneys. Indications for use Treatment and prevention of influenza A and B and other acute respiratory viral infections (adenoviral infection, parainfluenza, respiratory syncytial infection). Method of application and dosing regimen Inside, regardless of the meal. Dissolve the contents of the package in a glass of water, mix and drink as soon as possible. For the treatment of influenza and acute respiratory viral infections, adults are prescribed one packet once a day (90 mg). The duration of treatment is 5-7 days (depending on the severity of the condition). The drug is started from the moment the first symptoms of the disease appear, preferably no later than 2 days from the onset of the disease. For the prevention of influenza and acute respiratory viral infections after contact with sick persons, adults are prescribed one packet once a day (90 mg) for 7 days. You should not skip the next dose of the daily dose of the drug (the effect of skipping the next daily dose of the drug on the effectiveness of treatment has not been studied). If you miss the next daily dose of the drug, you should take the next dose as soon as possible and continue taking it once a day based on the new time of taking the drug (morning, afternoon, evening). Do not take a double dose of the drug. Special categories of patients Elderly patients: dose adjustment is not required. Patients with impaired liver and / or kidney function: dose adjustment is not required. Children and adolescents Not applicable to children under 18 years of age. Side effect The frequency of development of adverse reactions is given in the following gradation: rarely – may occur in less than 1 person out of 1,000. Allergic reactions (rarely). Reporting adverse reactions In case of adverse reactions, including those not listed in the instructions for use, you should consult a doctor. Contraindications – hypersensitivity to the active substance or any other component of the medicinal product; – pregnancy and lactation period; – children’s age up to 18 years. Overdose Cases of drug overdose are not described. Precautions The drug does not have a sedative effect, does not affect the speed of the psychomotor reaction and can be used in people of various professions, incl. requiring increased attention and coordination of movements. The simultaneous use of other antiviral drugs is not recommended. Use during pregnancy and lactation Pregnancy The use of the drug during pregnancy has not been studied. Breast-feeding period The use of the drug during breast-feeding has not been studied, therefore, if it is necessary to use the drug during this period, breast-feeding should be stopped. Influence on the ability to drive vehicles and other potentially dangerous mechanisms has not been studied, however, given the mechanism of action and the profile of adverse reactions, it can be assumed that the drug does not affect the ability to drive vehicles and mechanisms. Interaction with other drugs and other forms of interaction Cases of interaction of Vitavirin with other drugs have not been identified. Storage conditions In a place protected from moisture at a temperature not exceeding 25 ° C. Keep out of the reach of children. Shelf life 2 years. Do not use after the expiry date stated on the package. Packing 3.0 g in bags of multilayer packaging material (polyethylene terephthalate film/polypropylene film/aluminum foil/polyethylene film). 7 bags each with instructions for medical use in a pack of cardboard. Terms of dispensing from pharmaciesWithout a prescription. Buy Vitavirin powder for oral solution 90mg in bags #7